Holen Sie sich die Stockscreener-App
16.46
10.93%
-2.02
Handel nachbörslich:
16.40
-0.06
-0.36%
Beam Therapeutics Inc Aktie (BEAM) Neueste Nachrichten
Beam Therapeutics Becomes Oversold - Nasdaq
Is Beam Therapeutics Inc. (BEAM) the Best Gene-Editing Stock to Buy? - Yahoo Finance
8 Best Gene-Editing Stocks to Buy - Insider Monkey
Biotech stocks plunge as FDA’s Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard - TradingView
Beam Therapeutics’ SWOT analysis: base editing pioneer faces gene therapy hurdles - Investing.com Canada
Beam Therapeutics’ SWOT analysis: base editing pioneer faces gene therapy hurdles By Investing.com - Investing.com South Africa
The Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics - Yahoo Finance
BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance - MSN
Beam Therapeutics (BEAM) Upgraded by BofA on Promising Genetic T - GuruFocus
B of A Securities Upgrades Beam Therapeutics (BEAM) - MSN
Beam upgraded to Buy at BofA Securities on recent genetic condition treatment - Seeking Alpha
Beam Therapeutics stock rises after FDA clearance for BEAM-302 IND By Investing.com - Investing.com South Africa
Beam Therapeutics stock rises after FDA clearance for BEAM-302 IND - Investing.com
This Applied Materials Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday - Benzinga
B of A Securities Upgrades Beam Therapeutics (BMV:BEAM) - Nasdaq
Beyond The Numbers: 9 Analysts Discuss Beam Therapeutics Stock - Benzinga
BofA raises Beam Therapeutics stock rating to Buy, sets $42 target - Investing.com Canada
BofA raises Beam Therapeutics stock rating to Buy, sets $42 target By Investing.com - Investing.com South Africa
BofA Securities Upgrades Beam Therapeutics to Buy From Neutral - Marketscreener.com
FDA Clears Beam Therapeutics' (BEAM) Drug for Genetic Disease Tr - GuruFocus
Beam Therapeutics gets trial authorization for its genetic disorder treatment in U.S. - Seeking Alpha
Beam Therapeutics New Drug Application for Alpha-1 Antitrypsin Deficiency Gets FDA Clearance - Marketscreener.com
Beam Therapeutics’ BEAM-302 gains FDA’s nod for AATD treatment trial - Investing.com India
Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration - The Manila Times
Beam Therapeutics’ BEAM-302 gains FDA’s nod for AATD treatment trial By Investing.com - Investing.com Australia
Beam Therapeutics Announces Clearance Of Investigational New Drug Application For BEAM-302 For The Treatment Of Alpha-1 Antitrypsin Deficiency (AATD) By The United States (U.S.) Food And Drug Administration - Marketscreener.com
Beam Therapeutics Announces Clearance of Investigational - GlobeNewswire
Breakthrough: FDA Green Lights Beam's Revolutionary Gene Editing Drug for Rare Disease - Stock Titan
Beam Therapeutics (BEAM) Down 21.4% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Beam Therapeutics stock holds firm with $37 target at Bernstein By Investing.com - Investing.com South Africa
Cathie Wood’s ARK focuses on Beam Therapeutics, Intuitive Machines stock - Investing.com
Beam Therapeutics stock holds firm with $37 target at Bernstein - Investing.com
Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen - Benzinga
Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene Therapy - Seeking Alpha
Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN) - The Globe and Mail
Beam Therapeutics’ $500 Million Common Stock Offering - Global Legal Chronicle
Trading (BEAM) With Integrated Risk Controls - Stock Traders Daily
Prime sets sights on liver, lung disease as next target for its gene editing tech - BioPharma Dive
3 Gene Therapy Stocks to Watch Amid Industry Turmoil - Schaeffers Research
Beam Therapeutics (BEAM) Begins Dosing in Phase I/II AATD Study - MSN
Is Beam Therapeutics Inc. (BEAM) the Best Growth Stock to Invest in for the Next 10 Years? - Insider Monkey
BEAM Down Despite Positive Initial Data From Genetic Disorder Study - MSN
Wedbush Research Analysts Raise Earnings Estimates for BEAM - Defense World
Critical Survey: Adaptive Biotechnologies (NASDAQ:ADPT) vs. Beam Therapeutics (NASDAQ:BEAM) - Defense World
Citi lifts Beam Therapeutics stock price target to $64 - Investing.com India
Citi lifts Beam Therapeutics stock price target to $64 By Investing.com - Investing.com South Africa
Beam Therapeutics’ SWOT analysis: gene editing pioneer faces pivotal year for stock By Investing.com - Investing.com South Africa
Beam Therapeutics’ SWOT analysis: gene editing pioneer faces pivotal year for stock - Investing.com Australia
Beam Therapeutics Reports Clinical Proof-Of-Concept Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency Trial - CRISPR Medicine News
1.23%
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):